Somatic alterations frequently implicated in de novo AML, including FLT3, NPM1, and DNMT3A, are frequently not mutated, instead genes involved in the spliceosome modulator SRSF2 and in the epigenetic regulation of DNA, including IDH1/2, TET2, ASXL1, and EZH2 are mutated in bast phase MPN. This evidence concerns the gene TET2 and myeloproliferative disorder.